One more IPO listing is on its way, UPC is also getting itself listed in a general index. Well, its particulars aren’t disclosed yet, particulars like important dates and its issue price. They made public notice of their upcoming IPO. The IPO market is not in a very healthy state, as we all know the consequences of COVID-19 on the market. COVID fever is also affected badly; the whole world is suffering from this but is affected the most. Chinese medicinal drug manufacturing company is listing in NASDAQ: UPCat https://www.webull.com/quote/nasdaq-upcsoon.
- Dates to remember
- public notice for IPO-08/17/2020
- Lock updates- are not declared yet
- IPO price- $5-$7
- IPO size- not declared yet
Underwriter – Univest securities
To examine our IPO, let’s go through our E-I-C (economy –industry-company) approach
As we all know that COVID had disrupted the global as well national economy. Bad days for developing nations and the corporate of the world. The whole world is facing unprecedented moves. Monetary inflation, food inflation, hikes in diesel and petrol prices cued for higher volatility in the coming days. Gold mega and mini had shown inclined growth. The dollar went up in terms of INR. A lot of pessimism in the market. Not a good time to launch an IPO.
According to the received data from the nation bureau of statistics, China, 2018, those reports said that the Chinese people age 65 or more are 11.9% of the total population, which shows high demand of medicines shortly also because of rising in chronic diseases such as arthritis asthma, diabetes, etc. The report also presented a growth rate of the 65 years aged people, which expresses that the old age population will rise to 208 million by 2023, accounting for 14.7% of the total population of China. Well, all this data shows the growth of the pharmaceutical industry in the coming days. But this company will perform well till 2023?
Global cues are in red, but due to the rise in demand for medicinal drugs, this industry has a successful future ahead, might create a bubble.
Headquarter – Jiangxi, China
Founded – 1998
Their main products are chronic condition treatment medicines and cold and flu medicines. The trading symbol’ UPC.’ It will be listed on the NASDAQ: UPC capital market. This company has deep roots. Its parent company has passed many years of goodwill. Their major customers are hospitals, pharmacy companies, chemist drugstore chains.
Company’s financial status
- The company’s EPS (earnings per share) increased from 0.25 to 0.32.
- Rise in income from $ 4,046,202 to $5,074,076.
- Rise in company asset value from$17,836,879 to $ 26,776,539.
- Cash flow increased from $ 3, 177, and 32 to $11,796,452.
The company’s financial numbers and past stories showed a strong company with a healthy base.You can check more stocks like NASDAQ: OTRAU at https://www.webull.com/quote/nasdaq-otrau before investing.
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.